Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.
Pascal Richard David ClephasV W ZwartkruisJ MalgieM W F van GentH P Brunner-La RoccaM K SzymanskiV P van HalmM L HandokoW KokFolkert W. AsselbergsR van KimmenadeO ManintveldN M D A van MieghemSaskia Lambertha Maria Anna BeeresM C PostC J W BorleffsR TukkieA MosterdG C M LinssenR F SpeeM E EmansT D J SmildeJ van RamshorstC KirchhofF Feenema-AardemaC A da FonsecaM van den HeuveR HazelegerM van EckL van HeerebeekH BoersmaM RienstraR A de BoerJ J BrugtsPublished in: European heart journal (2024)
This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.
Keyphrases
- pulmonary artery
- ejection fraction
- phase iii
- coronary artery
- acute heart failure
- pulmonary hypertension
- study protocol
- pulmonary arterial hypertension
- end stage renal disease
- clinical trial
- phase ii
- randomized controlled trial
- heart failure
- open label
- atrial fibrillation
- patient reported outcomes
- cell therapy
- double blind